Entering text into the input field will update the search result below

OncoCyte's (OCX) CEO William Annett on Q4 2017 Results - Earnings Call Transcript

Apr. 02, 2018 7:00 PM ETOncoCyte Corporation (OCX)
SA Transcripts profile picture
SA Transcripts

OncoCyte Corporation (NASDAQ:OCX) Q4 2017 Earnings Conference Call April 2, 2018 4:30 PM ET


Michael Polyviou - Managing Member, EVC Group

William Annett - President & Chief Executive Officer

Cavan Redmond - Chairman of the Board of Directors

Mitch Levine - Chief Financial Officer

Lyndal Hesterberg - Senior Vice President, Research & Development


Bruce Jackson - Lake Street Capital Markets

Raymond Myers - Benchmark Company


Good day and welcome to the OncoCyte Conference Call to Discuss Fourth Quarter and Full-Year 2017 Financial Results. Today’s conference call is being recorded.

At this time, I’d like to turn the conference over to Michael Polyviou. Please go ahead.

Michael Polyviou

Thank you, Ashley. Thank you for joining us on this afternoon’s conference call and webcast to discuss OncoCyte’s fourth quarter and full-year 2017 financial results and recent developments. If you have not seen today’s press releases, please visit www.oncocyte.com.

Before turning the call over to Bill Annett, OncoCyte’s President and Chief Executive Officer, I would like to remind you that during this conference call, the company will make projections and forward-looking statements regarding future events. We encourage you to review the company’s filings with the SEC including without limitation the company’s forms 10-K and 10-Q, which identify the specific risk factors that may cause actual results or events to differ materially from those described in these forward-looking statements.

These factors may include without limitation, risks inherent in the development and/or the commercialization of potential diagnostic tests, uncertainty in the results of clinical trials or regulatory certifications, uncertainty in timing of the training reimbursement authorization from third-party payers, need and ability to obtain future capital and maintenance of intellectual property rights. Therefore, actual outcomes and results may differ materially from what is expressed or implied by these forward-looking statements. OncoCyte expressly disclaims any intent or obligation to update

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.